NewcelX shares rise 15.15% premarket after updated corporate presentation highlights Type 1 Diabetes focus and leadership additions.

NewcelX (NASDAQ: NCEL) surged 15.15% in premarket trading following the release of an updated corporate presentation on January 29, 2026. The presentation emphasized the company’s sharpened strategic focus on lead Type 1 Diabetes cell therapy programs, highlighted recent scientific progress, and announced the expansion of its Scientific Advisory Board and leadership team. These developments underscore NewcelX’s commitment to advancing regenerative medicine for endogenous insulin restoration and positioning for near- and mid-term value creation. The updates, coupled with plans to engage with investors and partners at upcoming conferences like BIO-Europe Spring, reinforced investor confidence in the company’s therapeutic pipeline and operational capabilities.